A Spain-based KOL opines about the most used agents in wet AMD with particular emphasis on the effect of cost and safety in making prescribing decisions. During the discussion, the KOL gives a glimpse of what the future might hold in terms of newer agents and combination therapy. The KOL also speaks about novel modes of administration and the impact of these on the current market. 

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only). 

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.